Companies Dominating the Acute liver failure Market
- Ipsen
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Gilead Sciences, Inc.
- Pfizer Inc.
- Novartis AG
- Bristol Myers Squibb
- AbbVie Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Zydus Pharmaceuticals Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT announced that the New Drug Application (NDA) for investigational elafibranor has been accepted by the U.S. Food and Drug Administration (FDA). Elafibranor, an experimental oral once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, may represent the first novel second-line treatment for the uncommon cholestatic liver disease PBC in almost ten years. June 10, 2024, is the target FDA PDUFA date that is being reviewed in priority.
- Gilead Sciences, Inc. (Nasdaq: GILD) announced that the FDA in the United States authorized a supplemental new drug application (sNDA) for the use of Remdesivir, or Veklury®, to treat COVID-19 in patients with mild, moderate, and severe hepatic impairment. The FDA approved the sNDA without requiring dose modifications. The safety profile of Veklury, the first and only antiviral COVID-19 therapy licensed for use across all stages of liver disease, is further supported by this approval.
